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The majority of patients with advanced cancer develop malnutri-
tion. This malnutrition has an important impact on quality of life,
performance status and immune status. It can be responsible for
increased morbidity, particularly infectious complications and
thus mortality. In five to more than 20% of patients with cancer,
death can be directly related to cachexia in the terminal phase
(Inagaki et al, 1974; Bozzetti, 1995).
OBJECTIVES
The objective is to define recommendations for the management of
nutrition in adult patients with progressive cancer in the terminal
phase.
The main questions addressed are:
 What are the different choices for management (oral feeding
and artificial nutrition)?
 What are the possible options for feeding considering the
clinical status and the preferences of the patient and their
family?
 What are the expected benefits and what criteria should be used
for follow-up and decision-making?
The aim of these recommendations is to describe the modalities
for palliative nutritional management and artificial nutrition in the
palliative phase. The aim of such management is to conserve or
restore the best possible quality of life and to control any
symptoms that are a source of discomfort or distress. The primary
objective cannot be to increase survival at any cost, or solely to
improve the nutritional status of the patient. The adverse effects
caused by nutritional interventions, particularly artificial nutrition,
are sometimes responsible for a deterioration in the quality of life
and thus can have a detrimental effect on the real objective of
palliative care. Decisions on whether or not to initiate, continue or
interrupt active nutritional management are particularly difficult.
Not supplying or stopping nutrition is often interpreted by the
patient, their family and/or the carers as an abandonment. Food is
strongly associated with the image of a potential source of life and
of energy.
METHODOLOGY
The general methodology used has already been described (Fervers
et al, 2001). For this specific SOR, a multidisciplinary working
group was set up by the French National Federation of Cancer
Centres (Fe ´de ´ration Nationale des Centres de Lutte Contre le
Concer – FNCLCC) to review the best available evidence on
palliative or terminal nutrition in adults with progressive cancer.
Medline
s was searched using a specific strategy for the period
1991 to April 2001. Web sites specialised in nutrition and palliative
care were also searched. The contents pages of the journals:
Supportive Care in Cancer and European Journal of Palliative Care
were screened from 1996 to 2000 (5 years). In addition, the
reference lists of the articles selected were analysed, and the
members of the working group provided references from their
personal sources.
Following the selection and critical appraisal of the articles, the
working group produced a document with the proposed ‘Stan-
dards’, ‘Options’ and ‘Recommendations’ (SORs) for palliative and
terminal nutrition in adults with progressive cancer.
When all the members of the working group agree, based on the
best available evidence, that a procedure or intervention is
beneficial, inappropriate or harmful, it is classified as a ‘Standard’,
and when the majority agree, it is classified as an ‘Option’ (Table 1).
In the SORs, there can be several ‘Options’ for a given clinical
situation. ‘Recommendations’ provide additional information that
enable the available options to be ranked using explicit criteria
(e.g. survival, toxicity) with an indication of the level of evidence.
These recommendations thus help clinicians to select an
appropriate option. Thus, clinicians can make choices for the
management of patients using this information and taking
into consideration local circumstances, skills, equipment,
resources and/or patient preferences. The adaptation of the
SOR to the local situation is allowable if the reason for the choice
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implementation. Inclusion of patients in clinical trials is an
appropriate form of patient management in oncology and is
recommended frequently within the SORs, particularly in situa-
tions where only weak evidence exists to support a procedure or an
intervention.
The type of evidence underlying any ‘Standard’, ‘Option’ or
‘Recommendation’ is indicated using a classification developed by
the FNCLCC based on previously published methods. The level of
evidence depends not only on the type and quality of the studies
reviewed, but also on the concordance of the results (Table 2).
When no clear scientific evidence exists, judgement is made
according to the professional experience and consensus of the
expert group (‘expert agreement’), and this is then validated by the
peer-review process.
The document was then peer-reviewed by independent experts,
and their comments were integrated in the final version. The
French summary version was based on the full version that has
been published (Bachmann et al, 2001) and both are available on
the FNCLCC web site (http://www.fnclcc.fr). The document will be
updated when new scientific evidence becomes available or when
there is new expert agreement.
Definition of palliative care
Palliative care and its organisation should be defined in a
consensual manner and controlled by regulations (standard).
Nutritional management is defined as a supportive treatment, and
in a palliative setting is part of the global management aimed at
maintaining or restoring ‘well-being’ (standard). Patients with a
life expectancy of less than a month can be considered to be in the
terminal phase of their illness (recommendation, expert agree-
ment). Patients with a life expectancy of at least 3 months or more,
or with an illness no longer responsive to curative treatment, are
considered to be in the palliative phase (recommendation, expert
agreement).
Clinical symptoms and prognostic factors
Gastrointestinal symptoms and nutritional problems are often
observed in patients with advanced cancer (standard, level of
evidence: B2). Functional scores (Karnofsky index and the WHO
performance status) have a good prognostic value in cancer and
should be used (standard, level of evidence: B2). Anorexia is a poor
prognostic factor in patients with advanced cancer (standard, level
of evidence: B2). A Karnofsky score of 50% or lower, or a
performance status higher than 2, is associated with a short life
expectancy in patients with advanced cancer (recommendation,
level of evidence: C). Dyspnoea is indicative of a poor short-term
(weeks) prognosis (recommendation, level of evidence: C). The
prognostic value of certain biological factors and quality of life
scores should be assessed in future prospective studies (recom-
mendation, expert agreement).
Organisation of management
In France, patients with advanced stage, progressive cancers are
cared for in hospital wards and specific palliative care units or at
home (standard). Wherever the patient is cared for, the manage-
ment should be multidisciplinary and the strategy should be
discussed with all the different actors involved (standard). The
patients and/or their families should be offered appropriate
support and whenever possible, their preferences should be
respected (standard). Locally written procedures should be
available for nutritional management (recommendation, expert
agreement).
Oral feeding
Dietary advice may help to increase feeding and to improve the
management of symptoms that interfere with feeding. Specific
diets (e.g. low-salt diet) should be stopped or made less strict in
order to allow for patients’ food preferences (standard). Standard
oral supplementation will increase the nutritional uptake in
patients with cancer undergoing active treatment (recommenda-
tion, level of evidence: B2). Increasing the oral supplementation of
eicosapentaenoic acid (EPA) may improve the nutritional status of
patients with cachexia secondary to pancreatic cancer (recom-
mendation, level of evidence: B2).
Symptomatic treatments
Medical treatment of symptoms is necessary in palliative manage-
ment (standard). Most of these treatments (apart from the appetite
stimulants) have not been evaluated in randomised controlled
Table 1 Definition of Standards, Options and Recommendations
Standards Procedures or treatments that are considered to be of
benefit, inappropriate or harmful by unanimous decision,
based on the best available evidence
Options Procedures or treatments that are considered to be of
benefit, inappropriate or harmful by a majority, based on the
best available evidence
Recommendations Additional information to enable the available options to be
ranked using explicit criteria (e.g. survival, toxicity) with an
indication of the level of evidence
Table 2 Definition of level of evidence
Level A
There exists a high-standard meta-analysis or several high-quality randomised clinical trials that give consistent results
Level B
There exist good quality evidence from randomised trials (B1) or prospective or retrospective studies (B2). The results are consistent when considered together
Level C
The methodology of the available studies is weak or their results are not consistent when considered together
Level D
Either the scientific data do not exist or there is only a series of cases
Expert agreement
The data do not exist for the method concerned, but the experts are unanimous in their judgement
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acetate, medroxyprogesterone acetate and corticosteroids have an
appetite stimulating effect (recommendation, level of evidence: B1)
and they may improve the quality of life for patients in the
palliative stage (recommendation). Patients with bowel obstruction
may benefit from a by-pass procedure, if they suffer from
distressing vomiting that cannot be controlled by medical
treatment and/or if their life expectancy is prolonged (43 months)
(recommendation, level of evidence: C).
Pharmaco-nutritional treatment of cachexia
Fish oil derivatives (EPA) may slow the rate of progression of the
cachexia (recommendation, level of evidence: B1) these should be
evaluated in future studies (recommendation).
Enteral nutrition
Enteral nutrition in a palliative setting can slow down nutritional
deprivation, avoid dehydration and improve the quality of life in
patients with head and neck cancer (standard, level of evidence: C).
The optimal modalities for delivery, administration and follow-up
are the same as those for enteral nutrition when given for other
indications (standard, expert agreement). In the terminal or
palliative stage, any complications and discomfort resulting from
enteral nutrition should be considered. In the event of any change
of treatment, the reasons for the change should be discussed with
the patients and their families and their preferences taken into
consideration (standard, expert agreement). Gastrostomy in
terminal-stage patients is associated with a risk of complications
that can be contrary to the objectives of palliative care. It is not
recommended in this situation (recommendation, level of
evidence: C).
Parenteral nutrition
Parenteral nutrition in the palliative setting can slow down
nutritional deprivation, avoid dehydration and improve the quality
of life in patients with a malignant bowel obstruction and/or other
causes of food intolerance (standard, level of evidence: C). The
modalities for delivery, administration and follow-up are the same
as those for parenteral nutrition when used for other indications
(standard, expert agreement). The benefits expected from par-
enteral nutrition should be reassessed at regular intervals or each
time that a complication related to the technique or the illness
occurs (recommendation, expert agreement). There is no justifica-
tion for parenteral nutrition in patients with a Karnofsky index of
50% or less, or with a performance status score higher than 2
(recommendation, expert agreement).
Hydration
Dehydration in the terminal phase is often neither painful nor
uncomfortable (standard, level of evidence: C). If hydration is
administered to control symptoms, the least invasive route
should be chosen, for example, the subcutaneous route, if
intravenous access is not available (recommendation, expert
agreement). Mouth washing is an important component of the
management (recommendation, expert agreement). Symptoms
can usually be controlled by the subcutaneous administration of
0.5–1.0l of 0.9% saline solution per 24h (recommendation, level
of evidence: C).
Therapeutic indications
Routine palliative artificial nutrition is not justified in patients in
the terminal phase of their disease since they often do not feel
hungry or thirsty, and the benefits have not been demonstrated
(standard, expert agreement). The objective of artificial nutrition
in a palliative situation is to improve the quality of life
(recommendation, expert agreement). This goal may be achieved
using artificial nutrition in patients who are unable to eat or to
absorb nutrients for a prolonged period of time, and in some of
these patients increased survival has been observed (recommenda-
tion, level of evidence: C). Artificial nutrition should not be started
if the patient’s life expectancy is less than 3 months and/or there is
any severe, permanent functional deficit (Karnofsky index of 50%
or less, or a performance status higher than 2) (recommendation,
expert agreement).
Treatment evaluation
The evaluation of the quality of the nutritional management in
patients with cancer in the palliative setting should include
assessment of functional scores, quality of life and the patient’s
(or their family’s) satisfaction (standard, expert agreement).
Measurement of the nutritional status and the complication rate
cannot be used to justify decisions about artificial nutrition, but
can be used to assess its quality (standard, expert agreement).
Clinical trials using appropriate, validated methodology should be
performed to evaluate this management (recommendation, expert
agreement).
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